Arca
Skip to content

Thrombocytopenia

Drug research and approvals for thrombocytopenia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 185 studies of thrombocytopenia are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 12 approved and 28 open orphan designations naming it, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 185
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 12
  • EU medicines: 7

Recruiting Now

Newest start dates first, of 185 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 11; search them all in Canada trials
May 26, 2026A phase 3, randomized, multicenter, open-label study to evaluate the efficacy and safety of romiplostim plus predniso(lo)ne vs. predniso(lo)ne alone for the…NPLATE (ROMIPLOSTIM)AmgenPending
Apr 21, 2026A randomized, multi-center, double-blind, phase . study evaluating the efficacy and safety of hetrombopag olamine tablets vs placebo in patients with…RAFUTROMBOPAG (HETROMBOPAG, SHR8735)Jiangsu Hengrui Pharmaceuticals Co., Ltd.Pending
Oct 18, 2024Double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of nipocalimab in reducing the risk of fetal and neonatal alloimmune…NIPOCALIMABJohnson & JohnsonPending
Nov 5, 2021An interventional phase 2, open-label, one-arm, multicenter study to evaluate safety and efficacy of pf-06835375 in adult participants with moderate to severe…PF-06835375PfizerClosed
Dec 1, 2020A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension to evaluate the efficacy and safety of…RILZABRUTINIB (PRN1008)PRINCIPIA BIOPHARMA INCOngoing
Jul 9, 2019An open-label, randomised, active controlled, multi-centre phase 3 study to evaluate the safety and efficacy of danaparoid vs argatroban in treatment of…ORGARAN (DANAPAROID SODIUM)Aspen Global IncOngoing
May 6, 2015A phase 3 randomised, double-blind, placebo-controlled study to assess the safety and efficacy of s-888711 (lusutrombopag) for the treatment of…LUSUTROMBOPAG (S-888711)ShionogiClosed
Nov 4, 2014A single arm, open-label, long-term efficacy and safety study of romiplostim in thrombocytopenic pediatric subjects with immune thrombocytopenia (itp)NPLATE (ROMIPLOSTIM)AmgenOngoing
Oct 10, 2014Open label, adaptive design, ascending, multiple-dose study to evaluate safety and efficacy of bms-986004 (anti-cd40l dab) in adult subjects with primary…BMS 986004 (ANTI-CD40L DOMAIN ANTIBODY)Bristol-Myers SquibbOngoing
May 9, 2014A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…PACRITINIB (SB1518)CTI BIOPHARMA CORPOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 40
Aug 29, 2025Wayrilztreatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous…Genzyme Corporation (A Sanofi Company)Approved
Jul 24, 2025Doptelettreatment of thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an…Sobi, Inc.Approved
Oct 17, 2019NplateNplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient…Amgen, Inc.Approved
Jun 26, 2019avatrombopag maleateDOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an…Sobi, Inc.Approved
Dec 14, 2018NplateNplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who…Amgen, Inc.Approved
Apr 17, 2018fostamatinib disodium hexahydrateTAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an…Rigel Pharmaceuticals, Inc.Approved
Mar 8, 2013GammaplexIdiopathic thrombocytopenic purpuraBio Products LaboratoryApproved
Nov 20, 2008PromactaTreatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response…Novartis Pharmaceuticals Corp.Approved
Aug 22, 2008NplateTreatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient…Amgen, Inc.Approved
May 19, 2004VidazaTreatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts…Celgene CorporationApproved
Mar 6, 1998RefludenFor anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further…Hoechst Marion RousselApproved
Nov 25, 1997NeumegaPrevention of severe chemotherapy-induced thrombocytopenia.Genetics Institute, Inc.Approved
Oct 24, 2026sovleplenib acetatetreatment of primary immune thrombocytopeniaHUTCHMED LimitedDesignated
Aug 22, 2026pirtobrutinibtreatment of primary immune thrombocytopeniaEli Lilly and CompanyDesignated
Jan 13, 2026a universal platelet-promoting megakaryocyte derived from…treatment of post-hematopoietic stem cell transplantation thrombocytopeniaHemaNiche Biotech Co., LtdDesignated

Medicines Authorised in the EU

Newest first
Dec 22, 2025Wayrilzrilzabrutinib · orphanSanofi B.V.EMA ↗
Mar 28, 2025Eltrombopag Accordeltrombopag · genericAccord Healthcare S.L.U.EMA ↗
Dec 12, 2024Eltrombopag Viatriseltrombopag · genericViatris LimitedEMA ↗
Jan 9, 2020TavlessefostamatinibInstituto Grifols S.A.EMA ↗
Jun 20, 2019DopteletavatrombopagSwedish Orphan Biovitrum AB (publ)EMA ↗
Mar 11, 2010RevoladeeltrombopagNovartis Europharm LimitedEMA ↗
Feb 4, 2009NplateromiplostimAmgen Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.